L&L Biopharma Co., Ltd.

Primary objectives: 1. To evaluate the safety and tolerability of LB1410 combined with LB4330 in adult patients with advanced solid tumors. 2. To determine the maximum tolerated dose (MTD) and/or the recommended dose (RP2D) of LB1410 combined with LB4330 in the dose escalation phase. 3. To evaluate the anti-tumor efficacy of LB1410 combined with LB4330. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of LB1410 combined with LB4330 in patients with advanced solid tumors. 2. To evaluate the immunogenicity (ADA) of LB1410 combined with LB4330. 3. To evaluate the relationship between ADA and PK, safety and efficacy of LB1410 combined with LB4330. 4. To detect PD-L1, TIM3, and Claudin18.2 in tumor tissues collected at baseline (test items are subdivided by tumor type). Exploratory objectives: ? Pharmacodynamic or potential biological predictive markers of LB1410 combined with LB4330: lymphocyte subsets (including CD8+ T cells, CD4+ T cells, etc.), cytokines.

Primary objectives: To evaluate the safety and tolerability of LB4330 in patients with advanced malignant solid tumors, explore the maximum tolerated dose (MTD) of LB4330, and determine the recommended dose (RP2D) for Phase II clinical trials. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of LB4330 in patients with advanced solid tumors. 2) To evaluate the immunogenicity of LB4330 in patients with advanced solid tumors. 3) To preliminarily evaluate the anti-tumor efficacy of LB4330 in patients with advanced solid tumors. 4) To preliminarily evaluate the biomarkers related to the efficacy of LB4330 in the treatment of patients with advanced malignant tumors, and provide a basis for the selection of treatment populations for Phase II clinical trials.